Humanigen Inc., a biopharmaceutical company focused on treating and preventing an uncontrollable inflammatory response by the immune system known as "cytokine storm," confirmed that lenzilumab is accessible now through its recently introduced Managed Access Program for specific hospitalized COVID-19 patients…
Continue Reading